FDA OKs Phase 1 clinical trial of IMPT-514 for hard-to-treat MS
The FDA has given Immpact Bio the green light for a Phase 1 clinical trial testing its IMPT-514 cell therapy in multiple sclerosis patients.
0 Comments
FDA OKs Phase 1 clinical trial of IMPT-514 for hard-to-treat MS
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed